Contact us: +91 9550333722 040 - 40102781
Structured search
India
Choose your country
Different countries will display different contents
Try our best to find the right business for you.
My chemicalbook

Welcome back!

HomeProduct name listBoxidine

Boxidine

Boxidine Structural

What is Boxidine?

Originator

Boxidine,Onbio Inc.

The Uses of Boxidine

Antihyperlipoproteinemic.

Definition

ChEBI: Boxidine is a member of biphenyls.

Manufacturing Process

The title compound may be prepared 2 ways:
1). 1-(2-[4'-(Trifluoromethyl)-4-biphenylyloxy]ethyl)pyrrolidine: A suspension consisting of 89.8 g (0.33 mole) of p-iodobenzotrifluoride, 132.5 g (0.65 mole) of p-iodoanisole, and 322.7 g of Cu powder in DMF (175 ml) was heated (225-230°C) with stirring in a resin pot for about 5 days. After cooling, the solid reaction mass was pulverized and continuously extracted (heptane) for 2 days. Evaporation of the solvent left a dark brown residue (ca. 50 g) which was dissolved (heptane, 200 ml), decolorized (charcoal), and concentrated to 100 ml. On standing ca. 20 g of impure 4,4'- dimethoxybiphenyl were deposited as colorless crystals. Fractional crystallization was continued until the crops of crystalline material were free of impurities by TLC (80:20 heptane-ethyl acetate). Pure 4-methoxy-4'- trifluoromethylbiphenyl was isolated as colorless granules, 21.6 g (26%), MP: 124-126°C. A solution consisting of 21.6 g (0.09 moles) of 4-methoxy-4'- trifluoromethylbiphenyl dissolved in glacial acetic acid and HBr (48%) was refluxed for approximately 24 hr. After cooling the acetic reaction mixture was poured into H2O (1.5 L) and the solid which separated was collected and air dried. 18.0 g (83%) of the crude product was isolated and taken up in Et2O (100 ml), decolorized (charcoal), filtered, and concentrated to one-third of the original volume. The material which separated from the Et2O solution (m.p. 147-148°C) was pure enough for the next synthetic step (structure verified by NMR). 1.5.6 g (0.06 mole) of the sodium derivative of 4-hydroxy-4'- trifluoromethylbiphenyl (prepared from 4-hydroxy-4'-trifluoromethylbiphenyl and sodium hydride) allowed to react with 8.0 g (0.06 mole) of 2- pyrrolidinylethyl chloride in refluxing DMF (100 ml) for 18 hr. The resulting suspension was cooled, filtered, and the clear filtrate was concentrated to semisolid residue. Two 100 ml portions of water were used to triturate the crude product which was then dissolved in benzene; the solution was decolorized (char coal) and dried (Na2SO4) and the benzene was removed. Several fractional crystallizations from acetone afforded 9.8 g (49%) of pure 1-1 2- [4'-(trifluoromethyl)-4-biphenylyloxy]ethyl)pyrrolidine MP: 109-110°C.
2). p-Bromobenzotrifluoride (1.37 g, 0.7 mole) and ca. 1.0 g of MeI dissolved in dry Et2O (200 ml) was added to 19 g (0.8 g-atom) of 11 g suspended in Et2O (20 ml) under the usual conditions. Addition of the aromatic halide was regulated to maintain a gentle reflux and refluxing was continued an additional 1 hr after addition was complete. 4-Methoxycyclohexanone (64 g, 0.5 mole) dissolved in 75 ml of dry Et2O was added to the freshly formed Grignard reagent with vigorous stirring and, after addition of the ketone was complete, the reaction mixture was refluxed with stirring for approximately 1 hr. Decomposition of the Grignard reagent-ketone addition product was achieved by adding excess cold, aqueous ammonia chloride (53 g in 1 L of H2O), and the crude product was removed using two 100-ml portions of Et2O. The combined extracts were decolorized (charcoal), filtered, and dried (Na2SO4). Removal of the Et2O left a brown, oily residue which was distilled in vacuum affording 51.3 g (38%) of 1-(p-trifluoromethylphenyl)-4- methoxycyclohexanol, b.p. 121-122°C (0.4-0.5 mm), m.p. 53-54°C.
The 4-methoxycyclohexanol derivative (27 g, 0.1 mole), purified as described above, was added to a vigorously stirred concentrated H2SO2-glacial acetic acid (10:40 ml) solution. When a clear solution resulted (ca. 2 min), the reaction mixture was poured all at once into a previously cooled (5-10% mixture of H2O (300 ml) covered with Et2O (300 ml)). The Et2O layer was separated, dried (Na2SO4), and concentrated to a brown, oily residue. Fractionation of the crude oil yielded 18.3 g (717) of 1-(ptrifluoromethylphenyl)- 4-methoxycyclohexene, b.p. 104-103°C (0.3-0.4 mm).
Dehydrogenation of the purified 4-methoxycyclohexene derivative, obtained as described above, was accomplished using a modification of the method described by Anisworth (J.A.C.S., 76, 4446 (1954)). A suspension consisting of 1-(p-trifluoromethylphenyl)-4-methoxycyclohexene (500 g, 1.95 moles), 166 g of Pd/C and nitrobenzene was refluxed for 22 hr. Aliquots of the reaction mixture taken periodically and analyzed by TLC (heptane-ethyl acetate (4:1) solvent system) indicated that aromatization was complete after this period of time, Removal of the nitrobenzene under reduced pressure left 442 g (89.9%) of the crude biphenyl derivative. Two recrystallizations (petroleum ether) produced material identical with that obtained from the 1 procedure described above.

Therapeutic Function

Antihyperlipidemic

Properties of Boxidine

Melting point: 108-110 °C(Solv: methanol (67-56-1); water (7732-18-5))
Boiling point: 415.4±45.0 °C(Predicted)
Density  1.178±0.06 g/cm3(Predicted)
pka 9.56±0.20(Predicted)

Safety information for Boxidine

Computed Descriptors for Boxidine

Related products of tetrahydrofuran

You may like

  • (R)-(3-(3-fluoro-4- thiomorpholinophenyl)-2- oxooxazolidin-4-yl) methyl methanesulfonate
    (R)-(3-(3-fluoro-4- thiomorpholinophenyl)-2- oxooxazolidin-4-yl) methyl methanesulfonate
    2416850-45-6
    View Details
  • methyl 3-fluoro-4- thiomorpholino phenylcarbamate
    methyl 3-fluoro-4- thiomorpholino phenylcarbamate
    2760359-22-4
    View Details
  • 5161-92-0
    5161-92-0
    5161-92-0
    View Details
  • Fuel shell 98%
    Fuel shell 98%
    View Details
  • 4,6-dichloro-2-propylthiopyrimidine-5-amine 145783-15-9 98%
    4,6-dichloro-2-propylthiopyrimidine-5-amine 145783-15-9 98%
    145783-15-9
    View Details
  • 151767-02-1 Montelukast Sodium IP/USP 98%
    151767-02-1 Montelukast Sodium IP/USP 98%
    151767-02-1
    View Details
  • Valacyclovir Hydrochloride IH 98%
    Valacyclovir Hydrochloride IH 98%
    124832-27-5
    View Details
  • 2-[2-[3(S)-3[2-(7-chloro-2-quinolinyl) ethenyl] phenyl-3- hydroxyl propyl] phenyl]-2-propanol 98%
    2-[2-[3(S)-3[2-(7-chloro-2-quinolinyl) ethenyl] phenyl-3- hydroxyl propyl] phenyl]-2-propanol 98%
    142569-70-8
    View Details
Statement: All products displayed on this website are only used for non medical purposes such as industrial applications or scientific research, and cannot be used for clinical diagnosis or treatment of humans or animals. They are not medicinal or edible.